Gleptosil 200mg/Ml Solution For Injection
Revised: June 2015
AN: 00261/2015
SUMMARY OF PRODUCTS CHARACTERISTICS
NAME OF THE VETERINARY MEDICINAL PRODUCT
Gleptosil 200mg/ml solution for injection
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance: Iron (as gleptoferron complex). Excipients: Phenol For a full list of excipients see Section 6.1 |
200 mg/ml 498 mg/ml) 5 mg/ml |
PHARMACEUTICAL FORM
Solution for injection.
A dark brown, slightly viscous, sterile, colloidal, aqueous solution
CLINICAL PARTICULARS
Target species
Neonatal pigs
Indications for use, specifying the target species
Neonatal pigs:
For the prevention and treatment of iron deficiency anaemia.
Contraindications
None
Special warnings for each target species
None
Special precautions for use
Special precautions for use in animals
Normal aseptic injection techniques should be practised.
Special precautions for the person administering the veterinary medicinal product to animals
Care should be taken to avoid accidental self injection.In the event of accidental self injection seek medical advice. Wash hands after use.
Other precautions
The sachet should not be opened until the product is required for use.
Avoid the introduction of contamination during use.
Adverse reactions (frequency and seriousness)
There are normally no undesirable side effects associated with the use of the product. Its use does not result in permanent staining of the injected muscle tissue.
Use during pregnancy, lactation or lay
Not applicable
Interaction with other medicinal products and other forms of interaction
There are no known interactions between the product and other medicaments. There are no known other forms of interaction. Do not mix with other products prior to administration.
Amount to be administered and administration route
Use only automatic syringe equipment
Swab the septum before use. The product is administered as a single 1 mL (200 mg iron) dose by deep intramuscular injection into the hind limb midway between the stifle joint and the base of the tail. Injections should be administered as follows:
FOR THE PREVENTION OF IRON DEFICIENCY ANAEMIA: not later than the third day of life. FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA: at the onset of clinical anaemia, normally within the first three weeks of life.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Overdosage with the product is unlikely to result in signs of intoxication.
Withdrawal period
MEAT AND OFFAL: ZERO DAYS.
PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Antianaemic preparations, Iron preparations, Iron trivalent, parenteral preparations
ATCVet Code: QBO3AC91
Pharmacodynamic properties
Injectable iron-carbohydrate complexes are established haematinic agents in veterinary medicine. Following intramuscular injection, the complex is absorbed and metabolised to release the iron for utilisation and/or storage in accordance with the nutritional status of the animal. In iron deficient states, the iron is utilised for the synthesis of haemoglobin and other iron-containing molecules. Excess iron is stored principally in the liver.
Pharmacokinetic properties
Absorption of the product has been shown to be rapid. Over 95% of the administered iron (1mL/200 mg iron administered at three days of age) was absorbed by 24 hours after injection. Use of the product does not result in permanent staining of the injected muscle tissue.
Environmental properties
Not applicable
PHARMACEUTICAL PARTICULARS
List of excipients
Phenol
Sodium chloride
Water for injections
Incompatibilities
None known
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after opening the immediate packaging: 28 days
Special precautions for storage
Do not store above 25°C. Protect from light.
Nature and composition of immediate packaging
100 mL clear colourless low-density polyethylene collapsible bottles with grey chlorbutyl rubber bung with aluminium overseal.
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
Ceva Animal Health Ltd
Unit 3, Anglo Office Park
White Lion Road
Amersham
Buckinghamshire
HP7 9FB
MARKETING AUTHORISATION NUMBER
Vm 15052/4079
DATE OF FIRST AUTHORISATION
Date:30 August 1995
DATE OF REVISION OF THE TEXT
Date:June 2015
Approved: 02 June 2015
Page 9 of 4